Can Aberrant DNA Methylation be Targeted for Therapy?
Yes, targeting aberrant DNA methylation is a promising strategy for cancer therapy. DNA methyltransferase inhibitors like azacitidine and decitabine have been approved for the treatment of certain types of cancer, such as myelodysplastic syndromes. These drugs work by inhibiting the enzymes responsible for adding methyl groups to DNA, thereby reactivating silenced tumor suppressor genes.
